Eevia Health Plc

Eevia Health PLC has received sales orders totaling KEUR 92 for its extracts from customers in Europe, Australia, and the US. Notable orders include KEUR 44 from NutriOriginal in the US for various organic mushroom and bilberry extracts, KEUR 18 from Ingredients Plus in Australia for elderberry extract, and KEUR 30 from a French trading partner for bilberry extract. These orders are repeat purchases, indicating strong customer demand and contributing positively to cash flow as the products are already in stock. Eevia expects continued repeat orders due to the growing interest in mushroom-based dietary supplements. For more information, contact Stein Ulve, CEO of Eevia Health. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company focuses on sustainability and operates a green-chemistry production facility. Eevia Health is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health PLC has received its first sales order from a new pilot customer for two of its liquid sugar concentrates, derived as side streams from berry extract production. This order is valued at approximately EUR 30,000. Eevia has been focusing on sustainability by valorizing its side streams, including liquid sugars and organic acids, which were previously discarded. The company has developed a new product, Liquid Sugar Concentrate, and successfully tested concentrating the liquid to 65% solids. The pilot customer, a North European berry product operator headquartered in Benelux, will receive eight tons of Bilberry Liquid Sugar concentrate and two tons of Tart Cherry Liquid Sugar concentrate. This development is expected to significantly enhance Eevia's product profitability. Eevia Health, founded in 2017, manufactures bioactive compounds from wild-harvested plant materials and operates a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden under the ticker EEVIA.

Eevia Health Plc's rights issue has been registered with the Finnish Trade Register, and the shares have been delivered to Euroclear Sweden and Euroclear Finland. The paid subscription shares will be replaced by ordinary shares, which will be booked into custodian accounts by August 22, 2024, and available on August 23, 2024. The last trading day for BTA on Spotlight Stock Market is August 19, 2024. The rights issue raised approximately SEK 17.2 million, increasing the number of shares from 35,713,884 to 64,355,488. Partner Fondkommission and OP Bank acted as financial advisers and issuing agents in Sweden and Finland, respectively. Eevia Health Plc, founded in 2017, produces bioactive compounds from wild-harvested plant materials, primarily from Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has received an 80,000 EUR sales order for customized lingonberry extracts from a renowned Finnish beauty brand. The end customer, a well-known manufacturer in the cosmetics industry, markets premium products across Europe, Asia, and North America, and is committed to sustainable development and natural Arctic product lines. The lingonberry extracts are standardized on key polyphenols and produced using a specialized processing protocol for this customer. This order is part of the expected repeat sales. Eevia Health Plc, founded in March 2017, focuses on addressing health problems with bioactive compounds from wild-harvested plant materials in Finland and Sweden. The company manufactures organically certified plant extracts for dietary supplements and food brands globally. Eevia Health emphasizes sustainable practices, operating a green-chemistry production facility in Finland, and listed its shares on the Spotlight Stock Market in Sweden in June 2021. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn @EeviaHealth.

Eevia Health Plc announced the results of its rights issue, which concluded on June 28, 2024, in Sweden and July 2, 2024, in Finland. A total of 28,360,404 shares were allocated, representing 59.6% of the offered shares. Existing shareholders subscribed to 18,629,364 shares with rights, while both existing and new shareholders subscribed to another 9,731,040 shares without rights. The company will issue 7,090,096 warrants of series TO1 and raise approximately SEK 17.0 million before costs, which are estimated at SEK 2.5 million. The funds will enhance working capital and repay a short-term bridge loan of SEK 7.5 million plus interest. The new shares are expected to be registered and delivered to subscribers by late July 2024. The rights issue will result in a 44.3% dilution for non-participating existing shareholders. Partner Fondkommission and OP Bank are the financial advisers and issuer agents for the offer in Sweden and Finland, respectively.

Eevia Health Abp has terminated its arrangement with Mangold Fondkommission as a liquidity provider for its shares on the Spotlight Stockmarket, citing sufficient natural liquidity. For further information, contact CEO Stein Ulve via email at stein.ulve@eeviahealth.com or investor@eeviahealth.com, or by phone at +358 400 22 5967. Eevia Health Plc, established in March 2017, produces bioactive compounds from plant materials, mostly wild-harvested in Finnish and Swedish forests. These extracts are used globally in dietary supplements and food brands. Eevia operates an environmentally friendly production facility in Finland and listed its shares on the Spotlight Stock Market in June 2021 under the ticker EEVIA. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn.

The Annual General Meeting of Shareholders of Eevia Health Plc took place on June 28, 2024, in Seinäjoki, Finland. Key resolutions included: 1. Adoption of the financial statements for 2023, with a net loss of EUR 885,795.22 transferred to retained earnings/loss account, and no dividends to be paid. 2. Discharge granted to the Board of Directors and CEO from liability for the financial year 2023. 3. Re-election of Martin Bjørklund, Per Benjaminsen, Oskar Wegelius, and Patricia Wiklund to the Board of Directors, with Martin Bjørklund as Chairman. 4. Approval of remuneration for the Board: EUR 16,000 for the Chairman and EUR 8,000 for other members, along with option rights for new shares. 5. Re-election of KPMG as auditor, with Mari Kaasalainen as the principal auditor, to be remunerated as per the approved invoice. For more information, contact CEO Stein Ulve at stein.ulve@eeviaheath.com or +358 400 22 5967. Eevia Health Plc, founded in 2017, produces bioactive compounds from wild-harvested plant materials in Finland and Sweden, offering ingredients for dietary supplements and food brands globally. The company emphasizes sustainable practices and operates a green-chemistry production facility. Eevia Health is listed on the Spotlight Stock Market in Sweden. More details are available at www.eeviahealth.com.

Eevia Health Plc has been collaborating with a major international ingredient house over the past year on the global sales of one of its ingredients. A successful feasibility study confirmed the ingredient's safety, and the project is now moving to clinical trials, rebranding, and worldwide commercial rollout. The ingredient house conducted various feasibility investigations, including safety studies, and Eevia has produced multiple industrial-scale batches while providing technical and scientific support. The next steps include initiating human clinical research and a full market launch, with a pre-launch set for May 2025 in some territories. This collaboration is separate from another partnership involving an eye health product. Eevia's CEO, Stein Ulve, highlighted that this opportunity will provide scientific validation and global sales reach for the ingredient, allowing Eevia to focus on other products. Eevia Health was founded in 2017 and specializes in bioactive compounds from wild-harvested plant materials, operating a green-chemistry production facility in Finland. The company is listed on the Spotlight Stock Market in Sweden.

Eevia Health Plc has received a first sales order worth 188 KEUR (2.1 MSEK) from a large international nutraceutical ingredients company for its Feno-Myrtillus® 25 Organic bilberry extract. This order is the result of an extensive engagement process and signifies Eevia's ability to compete with established brands. The company plans to ship half of the order immediately and the rest within weeks, positively impacting cash flow. The new customer is expected to place repeat orders, enhancing Eevia's market distribution and visibility. Eevia Health, founded in 2017, specializes in organic plant extracts primarily sourced from wild-harvested materials in Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and is listed on the Spotlight Stock Market in Sweden. For more information, visit their website or LinkedIn page.

Eevia Health Plc has received two sales orders totaling 68 KEUR (765 KSEK) from two European customers for its Feno-Myrtillus® organic extracts. One customer is a brand holder selling a bilberry supplement brand across Europe, and the other is an ingredient reseller in France. These repeat orders from stable customers highlight the trust and loyalty towards Eevia's products. The company has bilberry extracts in stock and will ship the orders immediately, positively impacting cash flow. Eevia Health, founded in 2017, produces bioactive compounds from wild-harvested plant materials in the Finnish and Swedish forests. The company operates a green-chemistry production facility in Finland and listed its shares on the Spotlight Stock Market in Sweden in June 2021. For more information, visit www.eeviahealth.com or follow Eevia Health on LinkedIn.